Zoetis (ZTS) Stock Rated Overweight as Key Franchises Remain Strong Amid Competition

Zoetis Inc. (NYSE:ZTS) ranks among the best medical stocks to buy according to analysts. With a price target of $210, Piper Sandler reaffirmed its Overweight rating on Zoetis Inc. (NYSE:ZTS) on July 2. According to the firm’s analysis, Zoetis’ 2025 guidance is unlikely to be negatively impacted by rising competition in its two largest franchises, dermatology and broad-spectrum parasiticides.

According to Piper Sandler, although Elanco’s Credelio Quattro launch was successful, the new product has largely contributed to market expansion rather than capturing a sizable portion of Zoetis’ market.

Based on the strength of its key businesses, Piper Sandler believes Zoetis Inc. (NYSE:ZTS) might still surpass revenue projections even if Librela, one of its products, may experience softness.

Global animal health provider Zoetis Inc. (NYSE:ZTS) focuses on delivering high-quality medications, vaccines, diagnostic tools, genetic testing, and services.

While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.